Cardiovascular Outcome Studies In Diabetes Drugs Finally Arrive

SAVOR-TIMI 53 A total of 16,492 people with type 2 diabetes at high risk for a cardiovascular event were studied in SAVOR-TIMI 53 . Participants wererandomized to the DPP-4 inhibitor saxagliptin (Onglyza, Bristol-Myers Squibb Bristol-Myers Squibb and AstraZeneca AstraZeneca ) or placebo. The primary endpoint (composite of CV death, MI, or ischemic stroke) occurred in 7.3% of the saxagliptin group and 7.2% in the placebo group (hazard ratio 1.0, CI 0.89-1.12, p=0.99 for superiority, p<0.001 for noninferiority). An important secondary endpoint, the composite of CV death, MI, stroke, hospitalization for unstable angina, coronary revascularization, or heart failure occurred in 12.8% of the treatment group versus 12.4% of the placebo group (HR 1.02, CI 0.94-1.11, p=0.66). There was an excess of hospitalization in the saxagliptin group compared with the placebo group: 3.5% versus 2.8% (HR1.27, CI 1.07-1.51, p=0.007).
For the original version including any supplementary images or video, visit

Furiex Confirms Alogliptin Cardiovascular Safety Outcomes Trial (EXAMINE) Met Primary Endpoint

12 is at 8 a.m. and the walk is at 8:30. For information on participating or to form a team, contact the Diabetes Foundation of Mississippi at 601-957-7878, 1-877-DFM-CURE or visit Down-home music and the first-ever 4-H Poultry Club competition will be featured at the Saturday Earth’s Bounty Festival, in addition to a bounty of fresh produce and homemade products, and health screenings provided by Greater Meridian Health Clinic. September 3, 2013 1 Photo It is because of the unselfish wishes from a young life that ended all too suddenly that others can live on. September 3, 2013 On Sept. 15 a 6 foot lighted cross will travel to Meridian for a Celebration Service.
For the original version including any supplementary images or video, visit

Young girl is hero for diabetes

Diabetes 2.jpg

Cardiovascular disease is very common in patients with Type 2 diabetes and the results of this study provide clinicians with assurance that alogliptin is effective and well-tolerated in these patients, and does not adversely affect cardiovascular health outcomes. EXAMINE was a large, randomized, double-blind, placebo-controlled global clinical trial, designed to evaluate CV safety following treatment with alogliptin in addition to standard of care, versus placebo in addition to standard of care alone, in patients with type 2 diabetes and a recent ACS. During the trial, patients were randomly assigned to receive alogliptin or placebo in addition to standard of care medications for diabetes and CVD. A total of 5,380 patients were randomly assigned and followed for a median of 18 months and up to 40 months. The rate of premature discontinuation of the study drug was similar in the alogliptin and placebo groups.
For the original version including any supplementary images or video, visit


Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s